0 XP   0   0   0

Tubize-Fin
Buy, Hold or Sell?

Should you buy, hold or sell Tubize-Fin?

I guess you are interested in Tubize-Fin. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Tubize-Fin

Let's start. I'm going to help you getting a better view of Tubize-Fin. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Tubize-Fin even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Tubize-Fin is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Tubize-Fin. The closing price on 2023-02-07 was €73.50 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Tubize-Fin Daily Candlestick Chart
Tubize-Fin Daily Candlestick Chart
Summary









1. Valuation of Tubize-Fin




Current price per share

€73.50

2. Growth of Tubize-Fin




Is Tubize-Fin growing?

Current yearPrevious yearGrowGrow %
How rich?$3.4b$2.9b$487m14.0%

How much money is Tubize-Fin making?

Current yearPrevious yearGrowGrow %
Making money$407.8m$279.5m$128.2m31.5%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Tubize-Fin




Comparing to competitors in the Biotechnology industry




  Industry Rankings (Biotechnology)  


Richest
#19 / 1232

Most Revenue
#907 / 1232

Most Profit
#12 / 1232

Most Efficient
#307 / 1232


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is efficient in making profit.
Using its investors money, the company is less efficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Tubize-Fin.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Tubize-Fin earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Tubize-Fin to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Tubize-Fin:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y1,891,400.8%-1,891,400.8%
5Y1,891,400.8%10Y945,744.8%+945,656.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--223.6%+223.6%
TTM--281.7%+281.7%
YOY--344.8%+344.8%
5Y1,891,400.8%-450.1%+1,891,850.9%
10Y945,744.8%-541.0%+946,285.8%
1.1.2. Return on Assets

Shows how efficient Tubize-Fin is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Tubize-Fin to the Biotechnology industry mean.
  • 11.6% Return on Assets means that Tubize-Fin generated €0.12 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Tubize-Fin:

  • The MRQ is 11.6%. Using its assets, the company is efficient in making profit. +1
  • The TTM is 11.6%. Using its assets, the company is efficient in making profit. +1
Trends
Current periodCompared to+/- 
MRQ11.6%TTM11.6%0.0%
TTM11.6%YOY9.2%+2.4%
TTM11.6%5Y11.0%+0.6%
5Y11.0%10Y8.4%+2.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.6%-9.9%+21.5%
TTM11.6%-8.9%+20.5%
YOY9.2%-9.3%+18.5%
5Y11.0%-11.7%+22.7%
10Y8.4%-12.7%+21.1%
1.1.3. Return on Equity

Shows how efficient Tubize-Fin is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Tubize-Fin to the Biotechnology industry mean.
  • 11.7% Return on Equity means Tubize-Fin generated €0.12 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Tubize-Fin:

  • The MRQ is 11.7%. Using its investors money, the company is less efficient in making profit.
  • The TTM is 11.7%. Using its investors money, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ11.7%TTM11.7%0.0%
TTM11.7%YOY9.3%+2.4%
TTM11.7%5Y11.5%+0.2%
5Y11.5%10Y9.0%+2.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.7%-12.0%+23.7%
TTM11.7%-11.5%+23.2%
YOY9.3%-10.8%+20.1%
5Y11.5%-14.2%+25.7%
10Y9.0%-15.2%+24.2%

1.2. Operating Efficiency of Tubize-Fin.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Tubize-Fin is operating .

  • Measures how much profit Tubize-Fin makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Tubize-Fin to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Tubize-Fin:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-7,466.8%+7,466.8%
5Y-7,466.8%10Y-3,723.7%-3,743.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.3%+207.3%
TTM--271.0%+271.0%
YOY--325.9%+325.9%
5Y-7,466.8%-454.0%-7,012.8%
10Y-3,723.7%-537.1%-3,186.6%
1.2.2. Operating Ratio

Measures how efficient Tubize-Fin is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Tubize-Fin:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y158.207-158.207
5Y158.20710Y79.114+79.092
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.871-2.871
TTM-3.504-3.504
YOY-3.604-3.604
5Y158.2075.132+153.075
10Y79.1146.371+72.743

1.3. Liquidity of Tubize-Fin.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Tubize-Fin is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 0.76 means the company has €0.76 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Tubize-Fin:

  • The MRQ is 0.761. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.761. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.761TTM0.7610.000
TTM0.761YOY0.030+0.731
TTM0.7615Y0.172+0.589
5Y0.17210Y0.090+0.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7615.117-4.356
TTM0.7615.755-4.994
YOY0.0305.854-5.824
5Y0.1726.511-6.339
10Y0.0906.222-6.132
1.3.2. Quick Ratio

Measures if Tubize-Fin is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Tubize-Fin to the Biotechnology industry mean.
  • A Quick Ratio of 0.76 means the company can pay off €0.76 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Tubize-Fin:

  • The MRQ is 0.759. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.759. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.759TTM0.7590.000
TTM0.759YOY0.029+0.731
TTM0.7595Y0.171+0.589
5Y0.17110Y0.089+0.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7594.284-3.525
TTM0.7594.664-3.905
YOY0.0294.787-4.758
5Y0.1715.218-5.047
10Y0.0895.182-5.093

1.4. Solvency of Tubize-Fin.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Tubize-Fin assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Tubize-Fin to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.01 means that Tubize-Fin assets are financed with 0.6% credit (debt) and the remaining percentage (100% - 0.6%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Tubize-Fin:

  • The MRQ is 0.006. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.006. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.006TTM0.0060.000
TTM0.006YOY0.012-0.006
TTM0.0065Y0.039-0.032
5Y0.03910Y0.087-0.049
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0060.278-0.272
TTM0.0060.277-0.271
YOY0.0120.306-0.294
5Y0.0390.367-0.328
10Y0.0870.403-0.316
1.4.2. Debt to Equity Ratio

Measures if Tubize-Fin is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Tubize-Fin to the Biotechnology industry mean.
  • A Debt to Equity ratio of 0.6% means that company has €0.01 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Tubize-Fin:

  • The MRQ is 0.006. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.006. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.006TTM0.0060.000
TTM0.006YOY0.012-0.006
TTM0.0065Y0.041-0.035
5Y0.04110Y0.099-0.058
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0060.315-0.309
TTM0.0060.317-0.311
YOY0.0120.319-0.307
5Y0.0410.403-0.362
10Y0.0990.462-0.363

2. Market Valuation of Tubize-Fin

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Tubize-Fin generates.

  • Above 15 is considered overpriced but always compare Tubize-Fin to the Biotechnology industry mean.
  • A PE ratio of 10.58 means the investor is paying €10.58 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Tubize-Fin:

  • The EOD is 8.608. Very good. +2
  • The MRQ is 10.575. Very good. +2
  • The TTM is 10.575. Very good. +2
Trends
Current periodCompared to+/- 
EOD8.608MRQ10.575-1.967
MRQ10.575TTM10.5750.000
TTM10.575YOY14.113-3.538
TTM10.5755Y10.817-0.242
5Y10.81710Y17.404-6.586
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.608-8.986+17.594
MRQ10.575-9.792+20.367
TTM10.575-16.243+26.818
YOY14.113-20.876+34.989
5Y10.817-16.665+27.482
10Y17.404-14.732+32.136
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Tubize-Fin.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Tubize-Fin:

  • The MRQ is 7.248. Seems overpriced? -1
  • The TTM is 7.248. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ7.248TTM7.2480.000
TTM7.248YOY15.369-8.121
TTM7.2485Y9.688-2.439
5Y9.68810Y16.704-7.016
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.248-0.032+7.280
TTM7.2480.004+7.244
YOY15.3690.016+15.353
5Y9.6880.006+9.682
10Y16.7040.003+16.701

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Tubize-Fin is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 1.24 means the investor is paying €1.24 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Tubize-Fin:

  • The EOD is 1.008. Good. +1
  • The MRQ is 1.238. Good. +1
  • The TTM is 1.238. Good. +1
Trends
Current periodCompared to+/- 
EOD1.008MRQ1.238-0.230
MRQ1.238TTM1.2380.000
TTM1.238YOY1.316-0.078
TTM1.2385Y1.223+0.015
5Y1.22310Y1.279-0.056
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.0081.835-0.827
MRQ1.2382.006-0.768
TTM1.2382.774-1.536
YOY1.3163.453-2.137
5Y1.2232.713-1.490
10Y1.2792.402-1.123
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Tubize-Fin compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--10.19810.1980%2.889+253%5.800+76%3.823+167%
Book Value Growth--1.1631.1630%1.048+11%1.107+5%1.079+8%
Book Value Per Share--72.94272.9420%62.744+16%59.110+23%48.779+50%
Book Value Per Share Growth--1.1631.1630%1.048+11%1.107+5%1.079+8%
Current Ratio--0.7610.7610%0.030+2423%0.172+343%0.090+746%
Debt To Asset Ratio--0.0060.0060%0.012-47%0.039-83%0.087-93%
Debt To Equity Ratio--0.0060.0060%0.012-47%0.041-84%0.099-94%
Dividend Per Share--0.6800.6800%0.620+10%0.584+16%0.534+27%
Dividend Per Share Growth--1.0971.0970%1.107-1%1.064+3%1.036+6%
Eps--8.5398.5390%5.853+46%6.717+27%4.691+82%
Eps Growth--1.4591.4590%0.918+59%1.190+23%1.328+10%
Free Cash Flow Per Share---0.026-0.0260%-0.047+80%-0.029+9%-0.024-10%
Free Cash Flow Per Share Growth--1.4451.4450%0.174+728%0.814+78%-0.274+119%
Free Cash Flow To Equity Per Share---1.039-1.0390%-1.885+81%-1.668+61%-1.308+26%
Free Cash Flow To Equity Per Share Growth--1.4491.4490%0.995+46%1.066+36%1.014+43%
Gross Profit Margin--1.0001.0000%1.000+0%1.000+0%1.000+0%
Intrinsic Value_10Y_max---0.162--------
Intrinsic Value_10Y_min---0.651--------
Intrinsic Value_1Y_max---0.024--------
Intrinsic Value_1Y_min---0.042--------
Intrinsic Value_3Y_max---0.066--------
Intrinsic Value_3Y_min---0.146--------
Intrinsic Value_5Y_max---0.101--------
Intrinsic Value_5Y_min---0.273--------
Net Profit Margin----0%-0%18914.008-100%9457.448-100%
Operating Margin----0%-0%-74.6680%-37.2370%
Operating Ratio----0%-0%158.207-100%79.114-100%
Pb Ratio1.008-23%1.2381.2380%1.316-6%1.223+1%1.279-3%
Pe Ratio8.608-23%10.57510.5750%14.113-25%10.817-2%17.404-39%
Peg Ratio--7.2487.2480%15.369-53%9.688-25%16.704-57%
Price Per Share73.500-23%90.30090.3000%82.600+9%72.196+25%62.028+46%
Price To Total Gains Ratio6.757-23%8.3018.3010%23.539-65%13.297-38%16.524-50%
Profit Growth--1.4591.4590%0.918+59%1.190+23%1.328+10%
Quick Ratio--0.7590.7590%0.029+2547%0.171+345%0.089+751%
Return On Assets--0.1160.1160%0.092+26%0.110+6%0.084+39%
Return On Equity--0.1170.1170%0.093+25%0.115+2%0.090+29%
Total Gains Per Share--10.87810.8780%3.509+210%6.384+70%4.357+150%
Total Gains Per Share Growth--3.1003.1000%0.444+598%2.366+31%2.093+48%
Usd Book Value--3483844298.0003483844298.0000%2996782773.000+16%2823978483.600+23%2331626961.300+49%
Usd Book Value Change Per Share--10.94210.9420%3.100+253%6.223+76%4.102+167%
Usd Book Value Per Share--78.26678.2660%67.324+16%63.425+23%52.340+50%
Usd Dividend Per Share--0.7300.7300%0.665+10%0.627+16%0.573+27%
Usd Eps--9.1629.1620%6.280+46%7.207+27%5.034+82%
Usd Free Cash Flow---1247899.000-1247899.0000%-2246862.000+80%-1366787.400+10%-1125147.800-10%
Usd Free Cash Flow Per Share---0.028-0.0280%-0.050+80%-0.031+9%-0.025-10%
Usd Free Cash Flow To Equity Per Share---1.115-1.1150%-2.022+81%-1.790+61%-1.403+26%
Usd Price Per Share78.866-23%96.89296.8920%88.630+9%77.466+25%66.556+46%
Usd Profit--407836570.000407836570.0000%279536887.000+46%320913483.800+27%224200989.400+82%
Usd Revenue----0%-0%120280510.200-100%129602412.300-100%
Usd Total Gains Per Share--11.67211.6720%3.765+210%6.850+70%4.675+150%
 EOD+3 -2MRQTTM+0 -0YOY+35 -35Y+36 -510Y+34 -7

3.2. Fundamental Score

Let's check the fundamental score of Tubize-Fin based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-158.608
Price to Book Ratio (EOD)Between0-11.008
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.759
Current Ratio (MRQ)Greater than10.761
Debt to Asset Ratio (MRQ)Less than10.006
Debt to Equity Ratio (MRQ)Less than10.006
Return on Equity (MRQ)Greater than0.150.117
Return on Assets (MRQ)Greater than0.050.116
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Tubize-Fin based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose73.700
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2021-12-31. Currency in EUR. All numbers in thousands.

Summary
Total Assets3,267,764
Total Liabilities20,938
Total Stockholder Equity3,246,826
 As reported
Total Liabilities 20,938
Total Stockholder Equity+ 3,246,826
Total Assets = 3,267,764

Assets

Total Assets3,267,764
Total Current Assets15,930
Long-term Assets15,930
Total Current Assets
Cash And Cash Equivalents 15,900
Net Receivables 1
Other Current Assets 30
Total Current Assets  (as reported)15,930
Total Current Assets  (calculated)15,931
+/- 1
Long-term Assets
Long-term Assets Other 3,251,834
Long-term Assets  (as reported)3,251,834
Long-term Assets  (calculated)3,251,834
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,938
Long-term Liabilities0
Total Stockholder Equity3,246,826
Total Current Liabilities
Short-term Debt 20,041
Short Long Term Debt 20,041
Accounts payable 467
Other Current Liabilities 430
Total Current Liabilities  (as reported)20,938
Total Current Liabilities  (calculated)40,979
+/- 20,041
Long-term Liabilities
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)0
+/-0
Total Stockholder Equity
Common Stock236,225
Retained Earnings 3,205,963
Other Stockholders Equity -195,362
Total Stockholder Equity (as reported)3,246,826
Total Stockholder Equity (calculated)3,246,826
+/-0
Other
Capital Stock236,225
Cash and Short Term Investments 15,900
Common Stock Shares Outstanding 44,513
Liabilities and Stockholders Equity 3,267,764
Net Debt 4,141
Net Invested Capital 3,266,867
Net Tangible Assets 3,246,826
Net Working Capital -5,008
Short Long Term Debt Total 20,041



Balance Sheet

Currency in EUR. All numbers in thousands.

 Trend2021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
525,305
647,273
748,105
791,029
715,254
1,018,916
1,595,335
1,674,974
1,585,273
1,723,704
1,784,905
1,868,665
1,785,998
1,804,734
1,835,424
2,259,155
2,222,819
2,311,329
2,483,601
2,751,764
2,827,158
3,267,764
3,267,7642,827,1582,751,7642,483,6012,311,3292,222,8192,259,1551,835,4241,804,7341,785,9981,868,6651,784,9051,723,7041,585,2731,674,9741,595,3351,018,916715,254791,029748,105647,273525,305
   > Total Current Assets 
0
0
0
11,583
10,103
12,527
9,671
8,884
8,916
2,812
764
789
200
504
388
612
689
1,485
1,662
526
1,033
15,930
15,9301,0335261,6621,4856896123885042007897642,8128,9168,8849,67112,52710,10311,583000
       Cash And Cash Equivalents 
130
308
191
588
4,877
7,190
9,658
8,869
8,793
2,798
757
779
193
476
354
565
662
1,452
1,529
462
983
15,900
15,9009834621,5291,4526625653544761937797572,7988,7938,8699,6587,1904,877588191308130
       Short-term Investments 
0
0
530
500
4,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000004,30050053000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
0
0
102
30
0
1
10301020013000000000000000
       Other Current Assets 
0
0
0
10,995
5,226
5,337
13
15
123
14
7
10
7
28
34
47
27
33
133
64
50
30
305064133332747342871071412315135,3375,22610,995000
   > Long-term Assets 
0
0
0
779,446
705,151
1,006,389
1,585,664
1,666,090
1,576,357
1,720,892
1,784,141
1,867,876
1,785,798
1,804,230
1,835,036
2,258,543
2,222,130
2,309,844
2,481,939
2,751,238
2,826,125
3,251,834
3,251,8342,826,1252,751,2382,481,9392,309,8442,222,1302,258,5431,835,0361,804,2301,785,7981,867,8761,784,1411,720,8921,576,3571,666,0901,585,6641,006,389705,151779,446000
       Property Plant Equipment 
1
1
0
0
0
0
0
8
0
4
2
0
0
0
0
0
0
0
0
0
0
0
0000000000024080000011
       Goodwill 
34,887
63,125
69,240
33,978
10,246
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000010,24633,97869,24063,12534,887
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
1,749,576
1,835,036
2,258,543
2,222,130
2,309,844
2,481,939
2,751,238
0
0
002,751,2382,481,9392,309,8442,222,1302,258,5431,835,0361,749,5760000000000000
       Intangible Assets 
34,887
63,125
69,240
33,978
10,246
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000010,24633,97869,24063,12534,887
       Long-term Assets Other 
0
0
0
779,446
705,151
1,006,389
1,585,664
1,666,090
1,576,357
1,720,888
1,784,139
1,867,876
1,785,798
1,804,230
1,835,036
2,258,543
2,222,130
2,309,844
2,481,939
2,751,238
2,826,125
3,251,834
3,251,8342,826,1252,751,2382,481,9392,309,8442,222,1302,258,5431,835,0361,804,2301,785,7981,867,8761,784,1391,720,8881,576,3571,666,0901,585,6641,006,389705,151779,446000
> Total Liabilities 
81,874
128,844
171,451
156,121
122,696
117,522
240,309
413,794
389,921
366,636
340,973
320,313
293,532
253,230
213,548
311,841
265,264
195,653
144,038
87,464
34,257
20,938
20,93834,25787,464144,038195,653265,264311,841213,548253,230293,532320,313340,973366,636389,921413,794240,309117,522122,696156,121171,451128,84481,874
   > Total Current Liabilities 
0
0
0
29,052
24,843
32,207
34,336
40,854
46,675
34,748
34,214
38,618
37,764
57,806
50,299
52,101
103,035
54,912
53,720
53,369
34,257
20,938
20,93834,25753,36953,72054,912103,03552,10150,29957,80637,76438,61834,21434,74846,67540,85434,33632,20724,84329,052000
       Short-term Debt 
0
0
0
0
22,533
29,780
29,533
0
29,533
30,000
30,000
35,000
35,000
55,192
46,053
48,350
99,997
52,144
52,613
52,561
33,516
20,041
20,04133,51652,56152,61352,14499,99748,35046,05355,19235,00035,00030,00030,00029,533029,53329,78022,5330000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
231,702
49,506
50,953
99,997
52,144
52,613
52,561
33,516
20,041
20,04133,51652,56152,61352,14499,99750,95349,506231,7020000000000000
       Accounts payable 
0
0
0
0
81
411
829
0
0
681
762
777
736
11
39
70
34
80
104
110
149
467
467149110104803470391173677776268100829411810000
       Other Current Liabilities 
0
0
0
29,052
2,229
2,016
3,974
40,854
17,142
4,067
4,214
3,618
2,028
2,603
4,207
3,681
3,004
2,688
1,003
698
592
430
4305926981,0032,6883,0043,6814,2072,6032,0283,6184,2144,06717,14240,8543,9742,0162,22929,052000
   > Long-term Liabilities 
0
0
0
127,069
97,853
85,315
205,973
372,940
343,246
331,888
306,759
281,695
255,768
195,424
163,249
259,740
162,229
140,741
90,318
34,095
0
0
0034,09590,318140,741162,229259,740163,249195,424255,768281,695306,759331,888343,246372,940205,97385,31597,853127,069000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
236,935
141,000
140,000
90,000
34,000
0
0
0034,00090,000140,000141,000236,935000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19,464
0
0
0
0
0
0000019,4640000000000000000
> Total Stockholder Equity
443,431
518,429
576,654
250,070
592,558
901,394
1,355,026
1,261,180
1,195,352
1,357,068
1,443,932
1,548,352
1,492,466
1,551,504
1,621,876
1,947,314
1,957,555
2,115,676
2,339,563
2,664,300
2,792,901
3,246,826
3,246,8262,792,9012,664,3002,339,5632,115,6761,957,5551,947,3141,621,8761,551,5041,492,4661,548,3521,443,9321,357,0681,195,3521,261,1801,355,026901,394592,558250,070576,654518,429443,431
   Common Stock
66,000
66,000
66,000
169,000
66,000
235,000
235,000
471,225
235,000
235,000
235,000
235,000
236,225
235,000
235,000
236,225
235,000
235,000
236,225
236,225
236,225
236,225
236,225236,225236,225236,225235,000235,000236,225235,000235,000236,225235,000235,000235,000235,000471,225235,000235,00066,000169,00066,00066,00066,000
   Retained Earnings Total Equity0000000000000000000000
   Accumulated Other Comprehensive Income 0000000000000000000000
   Capital Surplus 0000000000000000000000
   Treasury Stock00-137,558-126,808-130,844-102,256-104,268-59,424-61,237-86,482-95,031-45,289-45,324-48,811-49,482-48,529000000
   Other Stockholders Equity 
0
0
0
81,070
526,558
666,394
1,120,026
789,955
960,352
1,122,068
1,208,932
1,225
1,256,241
-22,481
9,976
172,151
-9,450
-98,120
-259,552
-201,006
-296,513
-195,362
-195,362-296,513-201,006-259,552-98,120-9,450172,1519,976-22,4811,256,2411,2251,208,9321,122,068960,352789,9551,120,026666,394526,55881,070000



Balance Sheet

Currency in EUR. All numbers in thousands.




Cash Flow

Currency in EUR. All numbers in thousands.




Income Statement

Currency in EUR. All numbers in thousands.


Latest Income Statement (annual, 2021-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-1,534
Operating Income-1,534-1,534
 
Operating Expense (+$)
Research Development-
Selling General Administrative493
Selling And Marketing Expenses39
Operating Expense1,534532
 
Net Interest Income (+$)
Interest Income-
Interest Expense-165
Net Interest Income-1,280-165
 
Pretax Income (+$)
Operating Income-1,534
Net Interest Income-1,280
Other Non-Operating Income Expenses-
Income Before Tax (EBT)380,090-383,158
EBIT - interestExpense = -1,522
380,090
380,255
Interest Expense165
Earnings Before Interest and Taxes (ebit)-1,357380,255
Earnings Before Interest and Taxes (ebitda)380,255
 
After tax Income (+$)
Income Before Tax380,090
Tax Provision-0
Net Income From Continuing Ops380,090380,090
Net Income380,090
Net Income Applicable To Common Shares380,090
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,534
Total Other Income/Expenses Net381,6241,280
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.